Collegium Pharmaceutical, Inc. Aktie News

STOUGHTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have four poster presentations highlighting real-world data from its ADHD product, Jornay PM (methylphenidate HCl), a central nervous system (CNS) stimulant indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in people 6 years of age and older and ...

On Dec. 8, 2025, the Executive Vice President and Chief Commercial Officer of Collegium Pharmaceutical sold 17,600 shares directly through an exercise of options. The sale represented 14.5% of Dreyer's direct holdings at the time, reducing his direct ownership to 103,613 shares.

– Product Revenues, Net Expected in the Range of $805 Million to $825 Million – – Jornay PM ® Net Revenue Expected in the Range of $190 Million to $200 Million – – Adjusted EBITDA* Expected in the Range of $455 Million to $475 Million – STOUGHTON, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), today announced its 2026 full-year financial guidance and pro...

STOUGHTON, Mass., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), today announced the closing of its inaugural syndicated credit facility.

STOUGHTON, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: Jefferies London Healthcare Conference Presentation Date and Time: Wednesday, November 19, 2025, at 8:00 a.m.

Collegium Pharmaceutical, Inc. just delivered standout Q3 results, with EPS and revenue significantly surpassing expectations, driving a 15% stock surge. COLL focuses on pain management treatments and expanded into ADHD with the recent Jornay PM acquisition, strengthening its product portfolio. Despite insider selling and a notable short interest, COLL maintains a strong cash position and manag...

Collegium Pharmaceutical, Inc. ( COLL ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Ian Karp Vikram Karnani - CEO, President, Executive VP & Director Scott Dreyer - Executive VP & Chief Commercial Officer Colleen Tupper - Executive VP & CFO Conference Call Participants Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Jeevan Larson - Truist Securities, In...

– Generated Record Quarterly Net Revenue of $209.4 Million, Up 31% Year-over-Year – – Generated Record Quarterly Jornay PM ® Net Revenue of $41.8 Million; Grew Prescriptions by 20% Year-over-Year – – Generated Record Quarterly Pain Portfolio Net Revenue of $167.6 Million, Up 11% Year-over-Year, with All Three Core Products Growing Year-over-Year – – Raised Full-Year 2025 Net Revenue Guidance to...